Inhibitors, Agonists, Screening Libraries
www.MedChemExpress.com
Data Sheet
Product Name:Cat. No.:CAS No.:
Molecular Formula:Molecular Weight:Target:Pathway:Solubility:
PrilocaineHY-B0137721-50-6C13H20N2O220.31
Na+/K+ ATPase
Membrane Transporter/Ion Channel10 mM in DMSO
BIOLOGICAL ACTIVITY:
Prilocaine is a local anesthetic of the amino amide type.Target: Others
Prilocaine is a local anesthetic of the amino amide type. In its injectable form (trade name Citanest), it is often used in dentistry. It isalso often combined with lidocaine as a preparation for dermal anesthesia, for treatment of conditions like paresthesia. As it has lowcardiac toxicity, it is commonly used for intravenous regional anaesthesia (IVRA). In some patients, a metabolite of prilocaine maycause the unusual side effect of methemoglobinemia, which may be treated with methylene blue. Maximum dosage for dental use: 8.0mg/kg (2.7 mg/lb), with a maximum dose of 500 mg.
Eutectic Mixture of Local Anesthetics (EMLA) containing 5% lidocaine and prilocaine in a cream was found to give effective topicalanalgesia in normal and diseased skin, making it useful for superficial surgery and various other clinical procedures. To be effective, anadequate amount must be applied under occlusion and at the right time before the intervention.
References:
[1]. Eriksson E. Prilocaine. An experimental study in man of a new local anaesthetic with special regards to efficacy, toxicity and excretion. Acta Chir ScandSuppl. 1966;358:1–82.
[2]. Juhlin L, et al. EMLA: a new topical anesthetic. Adv Dermatol. 1990;5:75–91; discussion 92.
Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-68 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
www.MedChemExpress.com
